NEW YORK (GenomeWeb News) — Invitrogen yesterday said that third-quarter revenues increased 7 percent while last year’s profit turned to a loss.
Total receipts fro the three months ended Sept. 30 increased to $311 million from $290 million year over year. Revenue grew 3 percent organically.
The company’s Biodiscovery segment grew 2 percent while the Cell Culture Systems segment grew 4 percent.

The company spent $26.8 million on research and development, nearly the same amount as the previous year’s third quarter.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.